Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric‐Bernstam, Shahneen Sandhu, Stefan Kasper et al.|Clinical Cancer Research|2022Cited by 226
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.Funda Meric‐Bernstam, Jason J. Luke, Neeltje Steeghs et al.|Journal of Clinical Oncology|2019Cited by 192